Autolus Therapeutics plc (FRA:6A3A)

Market Cap	279.52M -39.6%
Revenue (ttm)	64.21M +644.9%
Net Income	-244.89M
EPS	-0.92
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Average Volume	325
Open	1.150
Previous Close	1.130
Day's Range	1.150 - 1.180
52-Week Range	1.000 - 2.260
Beta	n/a
RSI	42.67
Earnings Date	Mar 27, 2026

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 649
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6A3A

Financial Performance

In 2025, Autolus Therapeutics's revenue was $75.39 million, an increase of 644.94% compared to the previous year's $10.12 million. Losses were -$287.53 million, 30.3% more than in 2024.

Financial numbers in USD